Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction

被引:53
|
作者
Piccini, Jonathan P. [1 ]
Schulte, Phillip J. [1 ]
Pieper, Karen S. [1 ]
Mehta, Rajendra H. [1 ]
White, Harvey D. [3 ]
de Werf, Frans Van [4 ,5 ]
Ardissino, Diego [6 ]
Califf, Robert M. [2 ]
Granger, Christopher B. [1 ]
Ohman, E. Magnus [1 ]
Alexander, John H. [1 ]
机构
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA
[2] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA
[3] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand
[4] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[5] Leuven Coordinating Ctr, Louvain, Belgium
[6] Parma Hosp, Parma, Italy
关键词
ventricular arrhythmia; antiarrhythmic drug therapy; clinical trials; acute coronary syndrome; ventricular tachycardia; ventricular fibrillation; PROPENSITY SCORE; BETA-BLOCKERS; MORTALITY; TRIAL; AMIODARONE; FIBRILLATION; TACHYCARDIA; DYSFUNCTION; LIDOCAINE; FAILURE;
D O I
10.1097/CCM.0b013e3181fd6ad7
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Few data exist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia/ventricular fibrillation after acute myocardial infarction. The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment. Design and Setting: We conducted a retrospective analysis of ST-segment elevation myocardial infarction patients with sustained ventricular tachycardia/ventricular fibrillation in Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO) IIB and GUSTO III and compared all-cause death in patients receiving amiodarone, lidocaine, or no antiarrhythmic. We used Cox proportional-hazards modeling and inverse weighted estimators to adjust for baseline characteristics, beta-blocker use, and propensity to receive antiarrhythmics. Due to nonproportional hazards for death in early follow-up (0-3 hrs after sustained ventricular tachycardia/ventricular fibrillation) compared with later follow-up (>3 hrs), we analyzed all-cause mortality using time-specific hazards. Patients and Interventions: Among 19,190 acute myocardial infarction patients, 1,126 (5.9%) developed sustained ventricular tachycardia/ventricular fibrillation and met the inclusion criteria. Patients received lidocaine (n = 664, 59.0%), amiodarone (n = 50, 4.4%), both (n = 110, 9.8%), or no antiarrhythmic (n = 302, 26.8%). Results: In the first 3 hrs after ventricular tachycardia/ventricular fibrillation, amiodarone (adjusted hazard ratio 0.39, 95% confidence interval 0.21-0.71) and lidocaine (adjusted hazard ratio 0.72, 95% confidence interval 0.53-0.96) were associated with a lower hazard of death-likely evidence of survivor bias. Among patients who survived 3 hrs, amiodarone was associated with increased mortality at 30 days (adjusted hazard ratio 1.71, 95% confidence interval 1.02-2.86) and 6 months (adjusted hazard ratio 1.96, 95% confidence interval 1.21-3.16), but lidocaine was not at 30 days (adjusted hazard ratio 1.19, 95% confidence interval 0.77-1.82) or 6 months (adjusted hazard ratio 1.10, 95% confidence interval 0.73-1.66). Conclusion: Among patients with acute myocardial infarction complicated by sustained ventricular tachycardia/ventricular fibrillation who survive 3 hrs, amiodarone, but not lidocaine, is associated with an increased risk of death, reinforcing the need for randomized trials in this population. (Crit Care Med 2011; 39:78-83)
引用
收藏
页码:78 / 83
页数:6
相关论文
共 50 条
  • [41] POTASSIUM - ITS RELEVANCE FOR ARRHYTHMIAS COMPLICATING ACUTE MYOCARDIAL-INFARCTION
    CAMPBELL, RWF
    HIGHAM, D
    ADAMS, P
    MURRAY, A
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1987, 10 : S25 - S28
  • [42] PLACE OF ANTIARRHYTHMIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION
    MCLINTIC, AJ
    TWEDDEL, A
    BRITISH HEART JOURNAL, 1986, 55 (05): : 522 - 523
  • [43] VENTRICULAR ANTIARRHYTHMIC ACTION OF FLECAINIDE IN ACUTE MYOCARDIAL-INFARCTION
    BAUR, HR
    CURTI, E
    GERTSCH, M
    ZEITSCHRIFT FUR KARDIOLOGIE, 1985, 74 : 85 - 85
  • [44] PROPHYLACTIC ANTIARRHYTHMIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION
    CAMPBELL, RWF
    AMERICAN JOURNAL OF CARDIOLOGY, 1984, 54 (11): : E8 - E10
  • [45] SHOULD PROPHYLACTIC ANTIARRHYTHMIC DRUG-THERAPY BE USED IN ACUTE MYOCARDIAL-INFARCTION
    HARRISON, DC
    BERTE, LE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (14): : 2019 - 2021
  • [46] VENTRICULAR ARRHYTHMIAS AND VENTRICULAR-FIBRILLATION IN ACUTE MYOCARDIAL-INFARCTION
    CAMPBELL, RWF
    MURRAY, A
    JULIAN, DG
    AMERICAN JOURNAL OF CARDIOLOGY, 1980, 45 (02): : 462 - 462
  • [47] ANTIARRHYTHMIC THERAPY FOR ASYMPTOMATIC VENTRICULAR ARRHYTHMIAS
    PRYSTOWSKY, EN
    AMERICAN JOURNAL OF CARDIOLOGY, 1988, 61 (02): : A102 - A111
  • [48] Antiarrhythmic Drug Therapy for Ventricular Arrhythmias: The Changing Role in the Modern Era
    Cuk, Natasha
    Braunstein, Eric. D. D.
    CARDIOLOGY, 2023, 148 (02) : 131 - 133
  • [49] INFLUENCE OF CLINICAL-DATA ON INDUCTION OF SUSTAINED VENTRICULAR ARRHYTHMIAS AFTER ACUTE MYOCARDIAL-INFARCTION
    RAVIELE, A
    DIPEDE, F
    LEVIMINZI, A
    ZUIN, G
    CAPRIOGLIO, F
    PICCOLO, E
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1985, 8 (03): : A104 - A104
  • [50] Intravenous antiarrhythmic drug therapy in the resuscitation from refractory ventricular arrhythmias
    Kudenchuk, PJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (9A): : 52R - 55R